Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Features include always present findings: Premature ovarian insufficiency, Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level, and Decreased circulating inhibin B concentration and others.
Organ System | Phenotype Count | Example Features |
|---|---|---|
Lab test results | 2 | Elevated circulating luteinizing hormone level, Elevated circulating follicle stimulating hormone level |
XRCC2 function has not been fully characterized.
Premature ovarian failure 17 is associated with mutations in the XRCC2 gene on chromosome 7.
Genetic testing for XRCC2 is available. Testing is considered confirmatory for diagnosis.
Biomarker and diagnostic research for premature ovarian failure 17 has been reported in the published literature.
Phenotype severity distribution: 6 always present features.
No clinical trials have been registered for premature ovarian failure 17.
91 publications have been identified in PubMed for premature ovarian failure 17. Research spans Epidemiology / Natural History (41%), Review / Meta-Analysis (29%), and Basic Science / Preclinical (13%).
Research Type | Count | % of Total |
|---|---|---|
Disease patterns and progression | 37 | 41% |
Data assembled from 5 of 12 sources · Last updated Sep 19, 2026, 4:32 PM UTC
Online Mendelian Inheritance in Man
Research summaries
26 |
29% |
Laboratory research | 12 | 13% |
Testing and diagnosis research | 5 | 5% |
Clinical study results | 4 | 4% |
Patient case studies | 3 | 3% |
Other research | 2 | 2% |
New treatment approaches | 2 | 2% |
Zhang Q (2026). [PMID: 41947243](https://pubmed.ncbi.nlm.nih.gov/41947243/). *Stem Cell Res Ther*. [Basic Science / Preclinical]
Wilson LM (2026). [PMID: 42010102](https://pubmed.ncbi.nlm.nih.gov/42010102/). *J Gen Intern Med*. [Epidemiology / Natural History]
Li LL (2026). [PMID: 41539956](https://pubmed.ncbi.nlm.nih.gov/41539956/). *Zhonghua Er Ke Za Zhi*. [Basic Science / Preclinical]
Li YX (2026). [PMID: 41669685](https://pubmed.ncbi.nlm.nih.gov/41669685/). *Front Pharmacol*. [Review / Meta-Analysis]
Zhou J (2026). [PMID: 41700296](https://pubmed.ncbi.nlm.nih.gov/41700296/). *Front Genet*. [Review / Meta-Analysis]
Zhong W (2026). [PMID: 41757233](https://pubmed.ncbi.nlm.nih.gov/41757233/). *Front Endocrinol (Lausanne)*. [Other]
Fan M (2026). [PMID: 41850610](https://pubmed.ncbi.nlm.nih.gov/41850610/). *J Affect Disord*. [Epidemiology / Natural History]
Liu X (2026). [PMID: 40705082](https://pubmed.ncbi.nlm.nih.gov/40705082/). *Naunyn Schmiedebergs Arch Pharmacol*. [Basic Science / Preclinical]
Saravinovska K (2026). [PMID: 42006274](https://pubmed.ncbi.nlm.nih.gov/42006274/). *Front Endocrinol (Lausanne)*. [Review / Meta-Analysis]
Li M (2026). [PMID: 41934138](https://pubmed.ncbi.nlm.nih.gov/41934138/). *BJOG*. [Epidemiology / Natural History]